News

GlobalData on MSN20h
Hengrui and Kailera report positive data from Phase III obesity treatment trial
Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) ...
Lilly’s Zepbound faces a potential weight-loss rival. It’s made by a Chinese biotech
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
InnovationRx: Hawley, Who Voted To Slash Medicaid, Introduces Bill To Reverse Cuts
In this week’s edition of InnovationRx, we look at how Daniel Nadler became a billionaire building a ChatGPT for doctors, big news from two Chinese biotech companies, what doctors think about AI and ...
BioSpace21h
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
Around 3,500 FDA employees received termination emails; FDA Commissioner Marty Makary suggests lowering industry user fees ...
Tariffs Are Showing Up in Inflation. Why Trump Can’t Afford to Ditch Powell.
House deals a blow to “Crypto Week,” ASML warns on 2026 growth, a promising Chinese weight-loss drug, and more news to start your day.
PipelineReview.com17h
Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
The trial results demonstrated a favorable safety and tolerability profile consistent with GLP-1-based treatments and previously reported HRS9531 Phase 2 clinical data. Most treatment-emergent adverse ...
The Pharma Letter14h
J&J jumps on improved outlook
Shares in US healthcare conglomerate Johnson & Johnson rose by 6% during Wednesday morning’s trading after the presentation ...